Fulcrum Therapeutics (NASDAQ:FULC) Releases Earnings Results, Beats Expectations By $0.06 EPS

Fulcrum Therapeutics (NASDAQ:FULC) released its earnings results on Monday. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.06, Zacks reports.

Here are the key takeaways from Fulcrum Therapeutics’ conference call:

• Phase Ib PIONEER data showed that 20 mg once-daily pociredir increased mean fetal hemoglobin (HbF) from 7.1% to 19.3% at 12 weeks, improved hemolysis and anemia markers, and seven of 12 patients experienced no VOCs, with no treatment-related serious adverse events reported.
• Fulcrum plans an end-of-phase meeting with the FDA this quarter and expects to provide a trial design update, targeting initiation of a potential registration‑enabling study in the second half of 2026 pending FDA feedback.
• The company ended Q1 with $333.3 million in cash and marketable securities, which management says provides financial runway into 2029 to advance pociredir through the next development stages.
• The open‑label long‑term dosing study has only just enrolled its first patient and faces site activation and roll‑over limitations, so robust longer‑term safety and durability data are unlikely to be available before 2027.

Fulcrum Therapeutics Price Performance

Shares of Fulcrum Therapeutics stock opened at $7.72 on Tuesday. The stock has a market cap of $514.15 million, a price-to-earnings ratio of -6.54 and a beta of 3.27. The firm’s 50-day moving average is $8.06 and its 200 day moving average is $9.55. Fulcrum Therapeutics has a 1 year low of $3.45 and a 1 year high of $15.74.

Hedge Funds Weigh In On Fulcrum Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. EntryPoint Capital LLC bought a new position in Fulcrum Therapeutics during the 4th quarter valued at about $171,000. Cubist Systematic Strategies LLC bought a new position in Fulcrum Therapeutics during the 1st quarter valued at about $164,000. Algert Global LLC bought a new position in Fulcrum Therapeutics during the 3rd quarter valued at about $152,000. WINTON GROUP Ltd bought a new position in Fulcrum Therapeutics during the 3rd quarter valued at about $149,000. Finally, Brevan Howard Capital Management LP bought a new position in Fulcrum Therapeutics during the 3rd quarter valued at about $141,000. Institutional investors own 89.83% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on FULC shares. Wall Street Zen downgraded shares of Fulcrum Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, April 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Tuesday, April 21st. JPMorgan Chase & Co. assumed coverage on shares of Fulcrum Therapeutics in a research note on Monday, January 12th. They issued an “overweight” rating and a $20.00 price target on the stock. Truist Financial set a $17.00 price target on shares of Fulcrum Therapeutics in a research note on Tuesday, February 24th. Finally, Leerink Partners reiterated an “outperform” rating on shares of Fulcrum Therapeutics in a research note on Tuesday, February 24th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $19.00.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.